[
  {
    "ts": null,
    "headline": "Novo Nordisk enters 2026 on the defense as it faces a ‘must-win’ battle in the U.S. market",
    "summary": "The FDA approval of the Wegovy pill highlights many of the key themes Novo Nordisk will have to face in 2026.",
    "url": "https://finnhub.io/api/news?id=ebb48c52df698182aadbf9ce9d6f8608ed7332cc56eea46a4d09aca75a587524",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767229201,
      "headline": "Novo Nordisk enters 2026 on the defense as it faces a ‘must-win’ battle in the U.S. market",
      "id": 137958517,
      "image": "https://image.cnbcfm.com/api/v1/image/108246546-1767089024859-gettyimages-2169095528-64393_48_ms_2683.jpeg?v=1767089034&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "The FDA approval of the Wegovy pill highlights many of the key themes Novo Nordisk will have to face in 2026.",
      "url": "https://finnhub.io/api/news?id=ebb48c52df698182aadbf9ce9d6f8608ed7332cc56eea46a4d09aca75a587524"
    }
  }
]